Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

Cardiac Biomarkers in 2022 – a Vital Tool for Emergency Care

“…A report from the ESC-EHRA EORP registry on atrial fibrillation describes elevated cTn levels in 31.9% of patients with atrial fibrillation, and elevated cTn levels were associated with a higher incidence of MACE and all-cause death. 48 A study published very recently tested the efficacy of the ESC 0/1 h algorithm in patients with prior coronary bypass and identified a good sensitivity/specificity or the rule-in/rule-out protocols (100% and 93.5%), but with lower efficacy in this study population compared to the general population (52% vs. 74%, p <0.01). 49 A study published by Ticinesi et al investigated the role of hs-cTn increase in elderly population presenting to the ED for chest pain and suspected AMI.…”

Coronary artery disease among patients admitted with atrial fibrillation and chest pain

“…In several studies, abnormal troponin elevation was related to the presence of ischemic heart disease and to adverse outcomes such as composite outcomes of stroke, ACS, revascularization and death [16][17][18]. Recently, a study by Vitolo et al [19] (ESC-EHRA EORP registry) has shown that elevated troponin in these patients has a prognostic value. However, others failed to demonstrate this association [20][21][22].…”